Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Ozempic

    Jump to

    • Novo Nordisk slashes Ozempic, Wegovy prices in India, to fend generic competition

      The Danish drugmaker said it will cut the price of the starting dose of Ozempic by 36 percent and that of Wegovy by 48 percent from April 1, making both medicines available at an effective daily cost of Rs 202 for entry‑level therapy.

    • Indian founder in UK says Ozempic helped lose 30kg in 8 months, but 'at a cost’. Lists side effects

      While acknowledging that the kilos dropped steadily, Aakanksha Sadekar Chauhan said the experience was accompanied by side effects that are rarely discussed online. These included digestive discomfort, reduced appetite that made even familiar meals difficult, and unexpected energy fluctuations.

    • Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price

      Eris launch coincides with a parallel entry by Natco Pharma, which will also bring its semaglutide injections to market on the first day of patent expiry tomorrow

    • Ozempic copies at Rs 1,290 in India as generic GLP-1 era starts

      Natco Pharma plans to make an injection for semaglutide — the active ingredient in both Ozempic and Wegovy — that will have a starting price of Rs 1,290 a month, on the first day the generics are allowed

    • US women inject fat from dead bodies to get hourglass figure: 'It’s like we’re recycling'

      The procedure is also in demand among people who’ve recently shed a lot of weight from using popular weight-loss supplements like Ozempic and Mounjaro.

    • 'Fatter than ever': Why did Trump mock a wealthy friend to make a point about US drug prices?

      US President Donald Trump mocked a wealthy friend’s use of Ozempic during a speech on rural healthcare, highlighting stark price differences between the US and other countries and pushing for reform.

    • Novo Nordisk gears up for December Ozempic launch in India: Report

      India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a critical battleground for drugmakers

    • Ozempic 2.0: How new GLP-1 weight loss pills and monthly shots could transform obesity treatment

      Next-generation pills and monthly injectables promise more choice, fewer side effects and broader health benefits.

    • Americans are microdosing obesity drugs, driven by 'thin is in' marketing blitz

      GLP-1 medications aren’t approved for use in people whose body mass index, or BMI, falls below 27.

    • Sun Pharma Q2 steady — Should investors pop the stock pill?

      While US generic sales would remain soft due to the reduced contribution of Revlimid, innovative medicine sales are expected to do well.

    • Ozempic-style medicines could help curb drinking and drug use, scientists hint at bold future

      A class of diabetes and weight-loss drugs, known as GLP-1 receptor agonists, may do far more than trim waistlines. Early studies reveal they could also ease alcohol, nicotine, and drug dependence by calming reward circuits in the brain. Discover how this breakthrough could reshape addiction treatment

    • Weight loss drug Ozempic launch in India: Is it safe for diabetes patients? Does it control blood sugar?

      Novo Nordisk’s weekly injection for type 2 diabetes, Ozempic, is set to launch in India. Here’s how it works, its benefits, risks, and impact on weight loss.

    • India bulk drug makers start preparing for Ozempic patent expiry

      Drugmakers in India — the world’s largest supplier of non-patented medicines — aim to tap what could be a $94 billion global opportunity by 2035

    • Ozempic weight loss might cost you muscle strength, says new study

      Ozempic has, in the recent times, become popular for weight loss, but new research hints it may hamper muscle strength, even if size stays the same. The results, from a mouse study, spark calls for human trials, especially for older adults vulnerable to weakness.

    • Green Coffee for Weight Loss? Indian Cricketer Sarfaraz Khan’s 17-kilo drop sparks buzz

      Cricketer Sarfaraz Khan’s stunning weight loss has sparked a wave of interest in Green coffee. With the public increasingly curious about natural alternatives to weight loss medications, his story is drawing attention to this modest, unroasted bean and its potential role in supporting healthy living without synthetic drugs

    • Ozempic side effect: Male users reveal change to their genitals after injection

      Men using the weight-loss drug claim to be experiencing 'Ozempic penis' phenomenon, sparking debate on online forums.

    • Mounjaro side effects revealed: Decreased appetite, mild nausea and more

      Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.

    • Is Ozempic beneficial for you? Nutritionist explains how it can diminish your natural glow

      Is Ozempic good for you? A nutritionist advises caution while using weight loss drugs. Here's what to keep in mind

    • Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential

      Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

    • Ozempic: A miracle weight-loss drug or dangerous trend? We examine

      With rumours circulating that Selena Gomez and other celebrities have used Ozempic, we reached out to experts to understand its benefits and whether it’s a one-stop solution for weight loss and diabetes management.

    • Trump Tariff – How much can it hurt Indian pharma?

      The first order impact will be a slow market share gain from innovators after a generic launch

    • Divis Lab: GLP-1 opportunity to unfold in the medium term

      Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.

    • Does Ozempic help in weight loss? Control blood sugar level, reduce hunger to stick to your fitness goals

      Ozempic is a medicine that helps control type 2 diabetes by helping your body regulate blood sugar levels better. Here are its best ways to take and side effects of Ozempic.

    • World Street | EU regulators probe Apple; Canada considers tariffs on China-made EVs; Nvidia stock tumbles; Shein files for London IPO, and more

      From EU regulator probing Apple, Canada mulling tariffs on China-made EVs to Nvidia stock tumbling 6 percent and Shein exploring a London listing , here's a look at recent business developments around the world.

    • How a pharma company is helping transform health of Denmark's economy

      The success of Novo Nordisk -- makers of Ozempic and Wegovy, shows the outsized effect a single company can have on a nation

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347